



Justification Document for the Selection of a CoRAP Substance

Substance Name (public name):	Formaldehyde, oligomeric reaction products with 1-chloro-2,3-epoxypropane and phenol
EC Number:	500-006-8
CAS Number:	9003-36-5
Authority:	DK MSCA
Date:	22/03/2016

Note

This document has been prepared by the evaluating Member State given in the CoRAP update.

Contents

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	7
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	8
3.1	Classification	8
3.1.1	Harmonised Classification in Annex VI of the CLP	8
3.1.2	Self classification	8
3.1.3	Proposal for Harmonised Classification in Annex VI of the CLP	8
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	9
4.1	Tonnage and registration status	9
4.2	Overview of uses	9
5.	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE	10
5.1.	Legal basis for the proposal	10
5.2.	Selection criteria met (why the substance qualifies for being in CoRAP)	10
5.3	Initial grounds for concern to be clarified under Substance Evaluation	10
5.4	Preliminary indication of information that may need to be requested to clarify the concern	12
5.5	Potential follow-up and link to risk management	12

1 IDENTITY OF THE SUBSTANCE

1.1 Other identifiers of the substance

Table: Other Substance identifiers

EC name (public):	500-006-8
IUPAC name (public):	Formaldehyde, oligomeric reaction products with 1-chloro-2,3-epoxypropane and phenol
Index number in Annex VI of the CLP Regulation:	-
Molecular formula:	Multi constituent substance
Molecular weight or molecular weight range:	<= 700.0
Synonyms:	<i>Araldite® GY 281;</i> <i>Araldite® GY 282;</i> <i>Araldite® GY 783;</i> <i>Araldite® PY 307-1;</i>

Type of substance Mono-constituent Multi-constituent UVCB

Structural formula:

















Table: Constituent

Name, CAS number, SMILES	Structural formula
2,2'-[propane-2,2-diylbis(benzene-4,1-diyloxymethanediyl)]dioxirane CAS RN: 1675-54-3 SMILES: <chem>CC(C)(c2ccc(OCC1CO1)cc2)c4ccc(OCC3CO3)cc4</chem>	
2-[[2-[2-[4-(oxiran-2-ylmethoxy)phenyl]propan-2-yl}phenoxy)methyl]oxirane CAS RN: N.A. SMILES: <chem>CC(C)(c2ccccc2OCC1CO1)c4ccc(OCC3CO3)cc4</chem>	
2,2'-[propane-2,2-diylbis(benzene-2,1-diyloxymethanediyl)]dioxirane CAS RN: N.A. SMILES: <chem>CC(C)(c2ccccc2OCC1CO1)c4ccccc4OCC3CO3</chem>	
2,2'-[methylenebis(p-phenyleneoxy methylene)]bisoxirane CAS RN: 2095-03-6 SMILES: <chem>C(C1CO1)Oc1ccc(Cc2ccc(OCC3CO3)cc2)cc1</chem>	
[[2-[p-(oxiranylmethoxy)benzyl]phenoxy)methyl]oxirane CAS RN: 57469-07-5 SMILES: <chem>C(C1CO1)Oc1ccccc1Cc1ccc(OCC2CO2)cc1</chem>	
2,2'-[methylenebis(o-phenyleneoxy methylene)]bisoxirane CAS RN: 54208-63-8 SMILES: <chem>C(C1CO1)Oc1ccccc1Cc1ccccc1OCC1CO1</chem>	

JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCES

<p>2,2',2''-[dimethylenetri(phenyleneoxy methylene)]trioxirane</p> <p>CAS RN: N.A.</p> <p>SMILES: N.A.</p>	
<p>2,2',2'',2'''-[trimethylenetetra(phenyleneoxymethylene)]tetraoxirane</p> <p>CAS RN: N.A.</p> <p>SMILES: N.A.</p>	
<p>2-Propanol, 1,3-bis[2,2'-[methylenedi(phenyleneoxymethylene)]bisoxirane]</p> <p>CAS RN: N.A.</p> <p>SMILES: N.A.</p>	
<p>1,2-Propanediol, 3-[2-[[4-(2-oxiranylmethoxy)phenyl]methyl]phenoxy]</p> <p>CAS RN: N.A.</p> <p>SMILES: N.A.</p>	
<p>3-[4-[[4-(2-oxiranylmethoxy)phenyl]methyl]phenoxy]-1,2-propanediol</p> <p>CAS RN: N.A.</p> <p>SMILES: OCC(O)COc3ccc(Cc2ccc(OCC1CO1)cc2)cc3</p>	
<p>1,2-Propanediol, 3-[2-[[2-(2-oxiranylmethoxy)phenyl]methyl]phenoxy]</p> <p>CAS RN: N.A.</p> <p>SMILES: OCC(O)COc1cccc1Cc2cccc2OCC3CO3</p>	


1.2 Similar substances/grouping possibilities

The substance is structurally similar to BPA Epoxy Resin which is nominated for the CoRAP list and under substance evaluation in 2015 with DK as the evaluating MSCA.

Table: Similar substance

EC number:	500-033-5
EC name (public):	4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane
CAS number:	25068-38-6
CAS name (public):	-
IUPAC name (public):	
Index number in Annex VI of the CLP Regulation:	603-074-00-8
Molecular formula:	N.A.
Molecular weight or molecular weight range:	≥ 340 - ≤ 700
Synonyms:	Bisphenol A, epichlorhydrin epoxy resin Average MW < 700. 2-(chloromethyl)oxirane; 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol; 4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane; Bisphenol A epoxy resin;

Structural formula:



2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

Table: Completed or ongoing processes

RMOA	<input type="checkbox"/> Risk Management Option Analysis (RMOA)	
REACH Processes	Evaluation	<input checked="" type="checkbox"/> Compliance check, Final decision The compliance check decision was issued by ECHA in 2012 and contained requests for substance ID related information.
		<input type="checkbox"/> Testing proposal
		<input type="checkbox"/> CoRAP and Substance Evaluation
	Authorisation	<input type="checkbox"/> Candidate List
		<input type="checkbox"/> Annex XIV
	Restriction	<input type="checkbox"/> Annex XVII
Harmonised C&L	<input type="checkbox"/> Annex VI (CLP) (see section 3.1)	
Processes under other EU legislation	<input type="checkbox"/> Plant Protection Products Regulation Regulation (EC) No 1107/2009	
	<input type="checkbox"/> Biocidal Product Regulation Regulation (EU) 528/2012 and amendments	
Previous legislation	<input type="checkbox"/> Dangerous substances Directive Directive 67/548/EEC (NONS)	
	<input type="checkbox"/> Existing Substances Regulation Regulation 793/93/EEC (RAR/RRS)	
Stockholm convention (POPs)	<input type="checkbox"/> Assessment	

	<input type="checkbox"/> In relevant Annex
Other processes/ EU legislation	<input checked="" type="checkbox"/> Other (provide further details below) Evaluated by EFSA for genotoxicity in 2005 http://www.efsa.europa.eu/de/scdocs/doc/274.pdf

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

No harmonised classification

3.1.2 Self classification

- In the registration:
 - Skin Irrit. 2 H315: Causes skin irritation.
 - Skin Sens. 1 H317: May cause an allergic skin reaction.
 - Aquatic Chronic 2 H411: Toxic to aquatic life with long lasting effects.

- The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:
 - Acute Tox. 3 H311
 - Eye Irrit. 2 H319
 - Aquatic Chronic 4 H413
 - Not classified

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

Not available

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site		
<input checked="" type="checkbox"/> Full registration(s) (Art. 10)	<input type="checkbox"/> Intermediate registration(s) (Art. 17 and/or 18)	
Tonnage band (as per dissemination site)		
<input type="checkbox"/> 1 – 10 tpa	<input type="checkbox"/> 10 – 100 tpa	<input type="checkbox"/> 100 – 1000 tpa
<input type="checkbox"/> 1000 – 10,000 tpa	<input checked="" type="checkbox"/> 10,000 – 100,000 tpa	<input type="checkbox"/> 100,000 – 1,000,000 tpa
<input type="checkbox"/> 1,000,000 – 10,000,000 tpa	<input type="checkbox"/> 10,000,000 – 100,000,000 tpa	<input type="checkbox"/> > 100,000,000 tpa
<input type="checkbox"/> <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa)		<input type="checkbox"/> Confidential

4.2 Overview of uses

Formaldehyde, oligomeric reaction products with 1-chloro-2,3-epoxypropane and phenol is used in coatings, in paints and adhesives, as monomers in the production of epoxy-based polymers and as additives.

Table: Uses

<input checked="" type="checkbox"/> Manufacture	<input checked="" type="checkbox"/> Formulation	<input checked="" type="checkbox"/> Industrial use	<input checked="" type="checkbox"/> Professional use	<input checked="" type="checkbox"/> Consumer use	<input checked="" type="checkbox"/> Article service life	<input checked="" type="checkbox"/> Closed system
---	---	--	--	--	--	---

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CoRAP SUBSTANCE



5.1. Legal basis for the proposal

- Article 44(2) (refined prioritisation criteria for substance evaluation)
- Article 45(5) (Member State priority)

5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

- Fulfils criteria as CMR/ Suspected CMR
- Fulfils criteria as Sensitiser/ Suspected sensitiser
- Fulfils criteria as potential endocrine disrupter
- Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB
- Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)
- Fulfils exposure criteria
- Fulfils MS's (national) priorities

5.3 Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns		
CMR <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	Suspected CMR ¹ <input type="checkbox"/> C <input type="checkbox"/> M <input type="checkbox"/> R	<input checked="" type="checkbox"/> Potential endocrine disruptor
<input type="checkbox"/> Sensitiser	<input type="checkbox"/> Suspected Sensitiser ¹	
<input type="checkbox"/> PBT/vPvB	<input type="checkbox"/> Suspected PBT/vPvB ¹	<input type="checkbox"/> Other (please specify below)
Exposure/risk based concerns		
<input type="checkbox"/> Wide dispersive use	<input type="checkbox"/> Consumer use	<input type="checkbox"/> Exposure of sensitive populations
<input type="checkbox"/> Exposure of environment	<input type="checkbox"/> Exposure of workers	<input type="checkbox"/> Cumulative exposure
<input type="checkbox"/> High RCR	<input type="checkbox"/> High (aggregated) tonnage	<input type="checkbox"/> Other (please specify below)
<p>Very limited <i>in vivo</i> information is available for endocrine related endpoints for the registered substance. In the registration dossier, read across is performed to the structurally similar substance BADGE (CAS 1675-54-3) to fill the standard information data gap on a two-generation reproductive toxicity study (OECD TG 416). In the robust study summary reported by the registrants there are no recordings of effects in this study which would raise a concern for endocrine disruption. The validity of the proposed read across has not been yet evaluated.</p> <p>A few <i>in vitro</i> studies on endocrine related endpoints are recorded from peer reviewed articles for BADGE and BFDGE which are constituents in the registered substance. According to Satoh <i>et al.</i> (2004) and Nakazawa <i>et al.</i> (2002) no estrogenic activity were identified when testing the parent compounds. However, both substances were found to have binding affinity to the androgen receptor and to display weak AR antagonist activity.</p> <p>One of the uses of the registered substance is to remove surplus hydrochloric acid in PVC production. The resulting chlorinated transformation products of BADGE and BFDGE have also been tested <i>in vitro</i>.</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>BADGE</p> <p>BADGE.2HCl</p> </div> <div style="text-align: center;">  <p>BFDGE</p> <p>BFDGE.2HCl</p> </div> </div> <p>Nakazawa <i>et al.</i> (2002) examined the estrogenic activity of BADGE.2HCl and BADGE.4OH (another BADGE transformation product) in the estrogen receptor (ER) alpha binding assay and in the breast cancer cell (T47D) proliferation assay. Both transformation products</p>		

¹ CMR/Sensitiser: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory)

Suspected CMR/Suspected sensitiser: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

displayed estrogenic activity in the cell proliferation assay but did not bind to the estrogen receptor. Based on this the authors indicate that these transformation products can display estrogenic activity through another mechanism than ER binding.

Satoh *et al.* (2004) did not identify estrogenic activity of BADGE.2HCl and BFDGE.2HCl in an estrogen receptor reporter gene assay. However, in an androgen receptor luciferase assay both transformation products displayed a high binding affinity for the androgen receptor and also strong AR antagonistic activity.

Based on the above cited *in vitro* studies on the transformation products of BADGE and BFDGE and on the lack of relevant *in vivo* data for endocrine related endpoints a concern is raised which should be investigated further. Therefore, the substance “Formaldehyde, oligomeric reaction products with 1-chloro-2,3-epoxypropane and phenol” has been nominated for the CORAP list with the purpose to clarify if the indicated concern for endocrine disrupting properties is realized or not.

References

Nakazawa, H., Yamaguchi, A., Inoue, K., Yamazaki, T., Kato, K., Yoshimura, Y., Makino, T. 2002. In vitro assay of hydrolysis and chlorohydroxy derivatives of bisphenol A diglycidyl ether for estrogenic activity. Food and Chemical Toxicology 40: 1827-1832.

Satoh, K., Ohyama, K., Aoki, N., Lida, M., Nagai, F. 2004. Study on anti-androgenic effects of bisphenol a diglycidyl ether (BADGE), bisphenol F diglycidyl ether (BFDGE) and their derivatives using cells stably transfected with human androgen receptor, AR-EcoScreen. Food and Chemical Toxicology 42: 983-993.

5.4 Preliminary indication of information that may need to be requested to clarify the concern

<input checked="" type="checkbox"/> Information on toxicological properties	<input type="checkbox"/> Information on physico-chemical properties
<input checked="" type="checkbox"/> Information on fate and behaviour	<input type="checkbox"/> Information on exposure
<input type="checkbox"/> Information on ecotoxicological properties	<input checked="" type="checkbox"/> Information on uses
<input checked="" type="checkbox"/> Information ED potential	<input type="checkbox"/> Other (provide further details below)

Different approaches may be considered in order to clarify the identified concern. Depending on the outcome of a more thorough evaluation it may be considered relevant to request test data to clarify the hazard profile (with a focus on ED properties) of the registered substance and/or its transformation products. Alternatively, it could be considered to first clarify the relevance of the transformation products in hazard or risk assessment of the registered substance (i.e. the degree of formation during the life cycle of the substance).

5.5 Potential follow-up and link to risk management

<input type="checkbox"/> Harmonised C&L	<input type="checkbox"/> Restriction	<input checked="" type="checkbox"/> Authorisation	<input type="checkbox"/> Other (provide further details)
---	--------------------------------------	---	--

If the substance is an endocrine disrupter a SVHC proposal should be considered.